Pharmacogenetics in solid organ transplantation: Present knowledge and future perspectives

Transplantation

Volumn 78, Issue 3, 2004, Pages 311-315

  Anglicheau, Dany ^a,b   Legendre, Christophe ^a   Thervet, Eric ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

AUTOSOMAL DOMINANT INHERITANCE; BONE MARROW SUPPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; GENE DOSAGE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; ORGAN TRANSPLANTATION; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ENZYMES; HUMANS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSPLANTS;

EID: 4143049173     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000136256.56873.41     Document Type: Review

References (32)

1. Kalow W, Tang BK, Endrenyi L. Hypothesis: Comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8(4): 283-289.
2. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348(6): 529-537.
3. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19-52.
4. Soria-Royer C, Legendre C, Mircheva J, et al. Thiopurine- methyltransferase activity to assess azathioprine myelotoxicity in renal transplant recipients. Lancet 1993; 341(8860): 1593-1594.
5. Chocair PR, Duley JA, Simmonds HA, et al. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53(5): 1051-1056.
6. Thervet E, Anglicheau D, Toledano N, et al. Long-term results of TMPT activity monitoring in azathioprine-treated renal allograft recipients. J Am Soc Nephrol 2001; 12(1): 170-176.
7. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360(9340): 1155-1162.
8. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74(3): 245-254.
9. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27(4): 383-391.
10. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76(8): 1233.
11. MacPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74(11): 1486-1489.
12. Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3(4): 477-483.
13. Turgeon DK, Leichtman AB, Blake DS, et al. Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test: A prospective study in renal transplant recipients. Transplantation 1994; 57(12): 1736-1741.
14. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47(6): 1048-1052.
15. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
16. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268(9): 6077-6080.
17. Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69(5): 308-316.
18. Kim RB. MDR1 single nucleotide polymorphisms: Multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12(6): 425-427.
19. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14(7): 1889-1896.
20. Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12(6): 451-457.
21. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43 (6): 555-564.
22. Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13(2): 89-95.
23. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR-1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75(5): 422-433.
24. Herweijer H, Sonneveld P, Baas F, et al. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990; 82(13): 1133-1140.
25. Naito M, Oh-hara T, Yamazaki A, et al. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother Pharmacol 1992; 29(3): 195-200.
26. Lan LB, Dalton JT, Schuetz EG. Mdrl limits CYP3A metabolism in vivo. Mol Pharmacol 2000; 58(4): 863-869.
27. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62(3): 248-260.
28. Yamauchi A, Ieiri I, Kataoka Y, et al. Neurotoxicity induced by tacrolimus after liver transplantation: Relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002; 74(4): 571.
29. Hebert MF, Dowling AL, Gierwatowski C, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13(11): 661-674.
30. Evans WE, McLeod HL. Pharmacogenomics: Drug disposition, drug targets, and side effects. N Engl J Med 2003; 348(6): 538-549.
31. Marshall SE, Bordea C, Haldar NA, et al. Glutathione S-transferase polymorphisms and skin cancer after renal transplantation. Kidney Int 2000; 58(5): 2186-2193.
32. Alamartine E, Berthoux P, Mariat C, et al. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol 2003; 120(1): 99-103.